AbbVie Inc. is a key player in the pharmaceuticals industry, offering a robust portfolio of therapies for various ailments. Its stock represents a promising opportunity with strong analyst support, while also facing challenges typical of the healthcare sector.
AbbVie Inc. has a fundamental rating score of 'B', indicating a positive financial standing with room for improvement in some areas.
Category | Score | Visualization |
---|---|---|
Discounted Cash Flow | 5 | |
Return on Equity | 5 | |
Return on Assets | 4 | |
Debt to Equity | 1 | |
Price to Earnings | 1 | |
Price to Book | 1 |
A comparison of historical scores provides insight into AbbVie Inc.'s financial trajectory.
Date | Overall Score | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
---|---|---|---|---|---|---|---|
2025-04-28 | 3 | 5 | 5 | 4 | 1 | 1 | 1 |
2025-04-25 | 3 | 5 | 5 | 4 | 1 | 1 | 1 |
Current analyst price targets suggest a potential growth trajectory within an established range.
High | Low | Median | Consensus |
---|---|---|---|
226 | 210 | 217.5 | 217.75 |
The majority of analysts favor a buying strategy, demonstrating confidence in AbbVie's market position.
Recommendation | Number | Distribution |
---|---|---|
Strong Buy | 0 | |
Buy | 26 | |
Hold | 11 | |
Sell | 0 | |
Strong Sell | 0 |
AbbVie Inc. showcases a solid performance with a proven track record in the healthcare industry, backed by analyst confidence. However, financial leverage remains a concern due to high debt-equity ratios. While growth opportunities are present, they are tempered by market competition and regulatory challenges. Investors should weigh these factors carefully when considering AbbVie's stock as a long-term investment option.
This structure includes all of the requested sections and utilizes classes only where necessary for score bars, aimed at integrating smoothly with any existing webpage styles.